高迁移率族蛋白B1水平与系统性血管炎相关性的Meta分析

朱晴; 朱彬; 吴婷; 洪静; 李南方

doi:10.16766/j.cnki.issn.1674-4152.001749

高迁移率族蛋白B1水平与系统性血管炎相关性的Meta分析

doi: 10.16766/j.cnki.issn.1674-4152.001749

新疆维吾尔自治区人民医院高血压中心新疆高血压研究所，新疆乌鲁木齐 830001

基金项目:

新疆维吾尔自治区自然科学基金项目 2019D01C105

详细信息

通讯作者:
李南方，E-mail：lnanfang2016@sina.com

中图分类号: R543 R446
计量
- 文章访问数: 110
- HTML全文浏览量: 53
- PDF下载量: 5
- 被引次数: 0
出版历程
- 收稿日期: 2019-05-08
- 网络出版日期: 2022-02-19

Meta-analysis of the relationship between HMGB1 level and systemic vasculitis

Hypertension Center, People's Hospital of Xinjiang Uygur Autonomous Region, Hypertension Institute of Xinjiang, Urumqi, Xinjiang 830001, China

摘要

摘要: 目的系统评价高迁移率族蛋白B1(high mobility group box 1, HMGB1)与系统性血管炎(systemic vasculitis, SV)的相关性，为评估HMGB1对SV诊断及疾病评估的临床价值提供依据。方法计算机检索PubMed、Medline、Web of science、Corchrane library、中国知网、万方和维普等数据库，检索时限为建库至2018年12月，收集所有关于HMGB1与SV的相关研究。由2名独立的评价者根据纳入及排除标准筛查文献，提取有效数据并运用Stata 12.0统计学软件进行Meta分析。结果最终纳入16项研究。研究显示，SV患者的HMGB1水平显著高于非活动期患者和健康对照组(HC)。亚组分析表明小血管炎和变应性血管炎患者的HMGB1水平显著高于HC。按区域进行亚组分析的结果显示，亚洲和欧洲SV患者的HMGB1水平显著增高。结论 Meta分析表明SV患者的HMGB1水平明显高于HC患者，且可以反应疾病的活动程度，但需进一步扩大样本量来确认研究结果。
- 高迁移率族蛋白B1 /
- 系统性血管炎 /
- 生物标记物 /
- Meta分析
Abstract: Objective To systematically evaluated the correlation between high mobility group protein B1 (HMGB1) and systemic vasculitis (SV), and provide basis for evaluating the clinical value of HMGB1 in the diagnosis of SV and disease assessment. Methods The studies focused on the association between the HMGB1 level and SV were searched in databases containing PubMed, Medline, Web of Science, Corchrane library, CNKI, Wanfang and VIP from the time of databases establishment to December 2018. Two independent evaluators screened literature according to according to inclusion and exclusion criteria, extracted relevant data, and then used Stata 12.0 software for meta-analysis. Results A total of 16 studies were finally included in the meta-analysis. Pooled data suggested HMGB1 levels were significant increased in SV patients compared with inactive patients and healthy controls (HC). The subgroup analysis indicated that HMGB1 levels in small vessel vasculitis and variable vessel vasculitis patients were significantly higher than that in the HC. With the subgroup analyses by region showed that HMGB1 levels were higher in Asia and Europe patients. Conclusion The meta-analysis indicates that HMGB1 levels are significant higher in patients with SV than in HC, and can reflect the disease activity. However, further enlargement of the sample size is needed to confirm the results.
- High mobility group box 1 /
- Systemic vasculitis /
- Biomarker /
- Meta-analysis

HTML全文

图 1 文献检索及筛查流程图

下载: 全尺寸图片幻灯片

图 2 SV组和HC组中HMGB1水平比较的森林图

下载: 全尺寸图片幻灯片

图 3 敏感性结果分析

下载: 全尺寸图片幻灯片

图 4 Begg's漏斗图评估发表性偏倚

下载: 全尺寸图片幻灯片

表 1 纳入文献的年龄和性别特征

第一作者	出版时间	区域	研究类型	疾病	样本量		年龄		性别(男/女，例)
第一作者	出版时间	区域	研究类型	疾病	病例	对照	病例	对照	病例	对照
DE SOUZA A^[24]	2014	荷兰	横断面	GPA	23	20	55.2(45.7, 62.4)	49.8(43.0, 57.4)	14/9	11/9
HENES F^[25]	2011	德国	病例对照	GPA	169	26	NA	NA	NA	NA
WIBISONO D E^[11]	2010	德国	病例对照	GPA	46	10	NA	NA	NA	NA
WANG C^[9]	2013	中国	病例对照	AAV	139	14	58.2±14.2	NA	63/76	NA
DE SOUZA A^[10]	2013	荷兰	病例对照	AAV	52	35	58.8±14.0	55.7±11.7	29/23	17/18
黄教文^[20]	2013	中国	病例对照	AAV	40	30	60.04±13.44	62.82±11.16	25/15	11/19
WIBISONO D E^[11]	2010	德国	病例对照	MPA	44	10	NA	NA	NA	NA
CHEN T^[26]	2014	中国	病例对照	HSP	44	36	23(10, 40)	20(11, 41)	21/23	17/19
王凤英^[23]	2015	中国	病例对照	HSP	40	30	7.4±2.1	7.2±2.0	23/17	17/13
甘世伟^[22]	2014	中国	病例对照	HSP	366	40	7.27±3.73	NA	208/158	NA
HOSHINA T^[13]	2008	日本	病例对照	KD	81	28	26.0±14.2	19.0±20.5	45/36	17/11
EGUCHI T^[12]	2009	日本	病例对照	KD	36	26	2.1±1.5	2.0±1.7	21/15	15/11
李艳飞^[21]	2013	中国	病例对照	KD	104	37	2.56±1.77	2.47±1.54	60/44	21/16
DE SOUZA A W^[15]	2015	荷兰	横断面	GCA	18	16	72.0(63.7, 75.0)	68.5(63.0, 72.0)	4/14	5/11
DE SOUZA A W^[15]	2015	荷兰	横断面	TA	29	29	38.0(34.5, 48.5)	38.0(27.5, 48.5)	1/28	2/27
DE SOUZA A W^[14]	2015	荷兰	横断面	BD	26	20	39.0±11.5	38.5±13.5	9/17	2/18
注：AAV为ANCA相关性血管炎；GPA为肉芽肿性多血管炎；MPA为显微镜下多血管炎；HSP为过敏性紫癜；KD为川崎病；TA为大动脉炎；GCA为巨细胞动脉炎；BD为白塞病。NA为未提供。

下载: 导出CSV

表 2 纳入文献的一般信息

第一作者	血HMGB1(x±s)		诊断标准	NOS
第一作者	病例	对照	诊断标准	NOS
DE SOUZA A^[24]	2.91±1.91	2.82±1.59	EMA	7
HENES F^[25]	4.68±3.66	2.34±2.01	ACR	7
WIBISONO DE^[11]	9.43±8.09	3.00±2.80	ACR	6
WANG C^[9]	6.22±7.05	1.27±0.48	CHCC	8
DE SOUZA A^[10]	2.64±1.80	2.39±1.09	EMA	7
黄教文^[20]	24.64±3.48	16.88±2.17	ACR	7
WIBISONO DE^[11]	2.61±2.56	3.00±2.80	ACR	6
CHEN T^[26]	56.67±41.04	30.28±16.37	NA	7
王凤英^[23]	15.7±3.4	7.8±1.7	中华医学会	7
甘世伟^[22]	8.69±1.66	7.54±0.72	NA	6
HOSHINA T^[13]	19.5±23.8	13.8±13.1	NA	6
EGUCHI T^[12]	2.40±1.40	2.70±0.80	JKDRC	6
李艳飞^[21]	39.75±17.01	12.31±5.28	JKDRC	6
DE SOUZA AW^[15]	5.74±4.19	4.17±3.14	ACR	7
DE SOUZA AW^[15]	1.84±2.22	2.12±2.10	ACR	7
DE SOUZA AW^[14]	4.01±2.65	1.11±0.55	ISG	8
注：EMA为欧洲药品管理局；CHCC为教堂山共识会议；ACR为美国风湿病学会；JKDRC为日本川崎病研究委员会；ISG为国际研究组。NA为未提供。

下载: 导出CSV

表 3 SV中HMGB1水平的亚组分析

组别	篇数	SMD(95% CI)	异质性检验
组别	篇数	SMD(95% CI)	Z值	P值	I²(%)	P值
疾病类型
SVV	10	0.91(0.41~1.42)	3.534	< 0.001	89.7	< 0.001
MVV	3	0.62(-0.62~1.86)	0.992	0.324	95.5	< 0.001
LVV	2	0.10(-0.43~0.63)	0.357	0.716	37.2	0.207
VVV	1	1.43(0.47~2.08)	4.283	< 0.001	-	-
区域
欧洲	8	0.40(0.05~0.75)	2.219	0.026	67.8	0.003
亚洲	6	1.17(0.51~1.83)	3.504	< 0.001	93.4	< 0.001
研究设计
病例对照	12	0.91(0.43~1.39)	3.718	< 0.001	91.3	< 0.001
横断面	4	0.43(-0.25~1.10)	1.242	0.216	79.7	0.002
Overall	16	0.79(0.39~1.20)	3.847	< 0.001	89.9	< 0.001
注：“-”表示仅一项研究，无合并后I²检验。

下载: 导出CSV

参考文献(29)

[1]	ELEFANTE E, MONTI S, BOND M, et al. One year in review 2017: systemic vasculitis[J]. Clin Exp Rheumatol, 2017, 103(1): 5-26. http://www.researchgate.net/profile/Sara_Monti2/publication/315790273_One_year_in_review_2017_Systemic_vasculitis/links/5a377e3445851532e832bf57/One-year-in-review-2017-Systemic-vasculitis.pdf
[2]	HATEMI G, ESATOGLU S N, YAZICI Y. Biomarkers in vasculitis[J]. Curr Opin Rheumatol, 2018, 30(1): 30-35. doi: 10.1097/BOR.0000000000000447
[3]	KURET T, LAKOTA K, ŽIGON P, et al. Insight into inflammatory cell and cytokine profiles in adult IgA vasculitis[J]. Clin Rheumatol, 2019, 38(2): 331-338. doi: 10.1007/s10067-018-4234-8
[4]	DEMIR S, SAG E, DEDEOGLU F, et al. Vasculitis in systemic autoinflammatory diseases[J]. Front Pediatr, 2018, 377(6): 1-10. doi: 10.3389/fped.2018.00377/pdf
[5]	DIENER K R, AL-DASOOQI N, LOUSBERG E L, et al. The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and cancer[J]. Immunol Cell Biol, 2013, 91(7): 443-450. doi: 10.1038/icb.2013.25
[6]	SUN X J, ZENG H Y, WANG Q S, et al. Glycyrrhizin ameliorates inflammatory pain by inhibiting microglial activation-mediated inflammatory response via blockage of the HMGB1-TLR4-NF-kappa B pathway[J]. Exp Cell Res, 2018, 369(1): 112-119. doi: 10.1016/j.yexcr.2018.05.012
[7]	VIJAY N, CHANDE A. A hypothetical new role for single-stranded DNA binding proteins in the immune system[J]. Immunobiology, 2018, 223(11): 671-676. doi: 10.1016/j.imbio.2018.07.013
[8]	WANG F Y, LI X Z, HUANG L S, et al. High-mobility group protein box 1 is upregulated in children with henoch-schonlein purpura[J]. Pediat Aller Imm Pul, 2018, 31(2): 66-72. http://smartsearch.nstl.gov.cn/paper_detail.html?id=5a823debb19a8d5e590accf99533614f
[9]	WANG C, GOU S J, CHANG D Y, et al. Association of circulating level of high mobility group box 1 with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis[J]. Arthritis Care Res, 2013, 65(11): 1828-1834. doi: 10.1002/acr.22187
[10]	DE SOUZA A, WESTRA J, BIJZET J, et al. Is serum HMGB1 a biomarker in ANCA-associated vasculitis?[J]. Arthritis Res Ther, 2013, 15(5): R104. doi: 10.1186/ar4284
[11]	WIBISONO D E, LAMPRECHT P, HOLLE J U, et al. Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis[J]. Ann Rheum Dis, 2010, 69(10): 1888-1889. doi: 10.1136/ard.2009.119172
[12]	EGUCHI T, NOMURA Y, HASHIGUCHI T, et al. An elevated value of high mobility group box 1 is a potential marker for poor response to high-dose of intravenous immunoglobulin treatment in patients with Kawasaki syndrome[J]. Pediatr Infect Dis J, 2009, 28(4): 339-341. doi: 10.1097/INF.0b013e31818ffe60
[13]	HOSHINA T, KUSUHARA K, IKEDA K, et al. High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease[J]. Scand J Rheumatol, 2008, 37(6): 445-449. doi: 10.1080/03009740802144143
[14]	DE SOUZA A W, FÉLIX P S, DE FRANA N R, et al. High mobility group box 1 serum levels are increased in Behçet's disease, but not associated with disease activity or disease manifestations[J]. Rheumatology, 2015, 54(12): 2151-2155. http://smartsearch.nstl.gov.cn/paper_detail.html?id=da49931fce08241f7970e81f36346812
[15]	DE SOUZA A W, KS VDG, BROUWER E, et al. High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins[J]. Arthritis Res Ther, 2015, 17(1): 158. doi: 10.1186/s13075-015-0672-8
[16]	STANG A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of non-randomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603-605. doi: 10.1007/s10654-010-9491-z
[17]	HOZO S P, DJULBEGOVIC B, HOZO I. Estimating the mean and variance from the median, range, and the size of a sample[J]. BMC Med Res Methodol, 2005, 5(1): 13. doi: 10.1186/1471-2288-5-13
[18]	WHITLOCK R P, CHAN S, DEVEREAUX P J, et al. Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials[J]. Eur Heart J, 2008, 29(21): 2592-2600. doi: 10.1093/eurheartj/ehn333
[19]	HIGGINS J P, THOMPSON S G. Quantifying heterogeneity in a meta-analysis[J]. Stat Med, 2002, 21(11): 1539-1558. doi: 10.1002/sim.1186
[20]	黄教文, 孙建平, 高延霞, 等. 高迁移率族蛋白B₁在抗中性粒细胞胞浆抗体相关性小血管炎患者血清中的表达水平及临床意义[J]. 中华临床医师杂志(电子版), 2013, 7(1): 188-189. doi: 10.3877/cma.j.issn.1674-0785.2013.01.076
[21]	李艳飞, 金莲花, 杨思睿, 等. 血清HMGB1、MIF、IL-6水平在川崎病患儿中的临床意义[J]. 中国实验诊断学, 2013, 17(6): 1087-1090. doi: 10.3969/j.issn.1007-4287.2013.06.034
[22]	甘世伟, 赵林胜, 王燕. HMGB1在过敏性紫癜患儿血清中的表达及其临床意义[J]. 重庆医科大学学报, 2014, 39(12): 1767-1770. https://www.cnki.com.cn/Article/CJFDTOTAL-ZQYK201412020.htm
[23]	王凤英, 蒋星美, 鲁曼. 高迁移率族蛋白1在过敏性紫癜患儿血清中的表达及意义[J]. 中国当代儿科杂志, 2015, 17(8): 792-795. https://www.cnki.com.cn/Article/CJFDTOTAL-DDKZ201508006.htm
[24]	DE SOUZA A, LEEUW K, VAN TIMMEREN M, et al. Impact of serum high mobility group box 1 and soluble receptor for advanced glycation end-products on subclinical atherosclerosis in patients with granulomatosis with polyangiitis[J]. PLoS One, 2014, 9(4): e96067. doi: 10.1371/journal.pone.0096067
[25]	HENES F, CHEN Y, BLEY T, et al. Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener's)[J]. Ann Rheum Dis, 2011, 70(11): 1926-1929. doi: 10.1136/ard.2010.146456
[26]	CHEN T, GUO Z P, WANG W J, et al. Increased serum HMGB1 levels in patients with Henoch-Schönlein purpura[J]. Exp Dermato, 2014, 23(6): 419-423. doi: 10.1111/exd.12422
[27]	YANG H, WANG H, CHAVAN S S, et al. High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule[J]. Mol Med, 2015, 21(Suppl 1): S6-S12. http://www.ncbi.nlm.nih.gov/pmc/picrender.fcgi?artid=PMC4661054&blobtype=pdf
[28]	WANG C, DE SOUZA A W, WESTRA J, et al. Emerging role of high mobility group box 1 in ANCA-associated vasculitis[J]. Autoimmun Rev, 2015, 14(11): 1057-1065. doi: 10.1016/j.autrev.2015.07.010
[29]	ANDERSSON U, TRACEY K J. HMGB1 is a therapeutic target for sterile inflammation and infection[J]. Annu Rev Immunol, 2011, 29(1): 139-162. doi: 10.1146/annurev-immunol-030409-101323